← All trials
NCT04601116
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 21, 2020
- Primary completion
- Sep 1, 2024
- Completion date
- Sep 1, 2034
- First posted
- Oct 23, 2020
- Last posted
- Oct 23, 2020
- Enrollment
- 3360
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aarhus UniversityLead sponsor
- Aarhus UniversityReponsible party - principal investigator
- Aarhus UniversityOverall official - principal investigator
- University of Southern DenmarkCollaborator
- University of CopenhagenCollaborator
- Region SyddanmarkCollaborator
- Herning HospitalCollaborator
- Naestved HospitalCollaborator
- Aalborg UniversityCollaborator
- Bornholms RegionskommuneCollaborator
- Sygehus SønderjyllandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.